or Try an Advanced Search...

    Technical Analysis for ALGS - Aligos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.68 -1.79% -0.01
    ALGS closed down 1.79 percent on Wednesday, May 15, 2024, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ALGS trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Inside Day Range Contraction -1.79%
    Below Lower BB Weakness -1.79%
    Lower Bollinger Band Touch Weakness -1.79%
    Oversold Stochastic Weakness -1.79%
    Older End-of-Day Signals for ALGS ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 17 hours ago
    Possible NR7 about 17 hours ago
    Possible Inside Day about 17 hours ago
    Rose Above Lower Bollinger Band about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ALGS Chart by TradingView
    Basic chart:

    Profile

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection

    Is ALGS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
    May 8 Aligos Therapeutics reports Q1 results
    May 7 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
    Apr 30 Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
    Apr 25 Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
    Apr 25 Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
    Apr 9 Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
    Apr 3 Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    Mar 27 Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
    Mar 27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
    See more ALGS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.22
    52 Week Low 0.54
    Average Volume 328,435
    200-Day Moving Average 0.78
    50-Day Moving Average 0.88
    20-Day Moving Average 0.77
    10-Day Moving Average 0.76
    Average True Range 0.07
    RSI (14) 33.33
    ADX 19.79
    +DI 12.61
    -DI 23.84
    Chandelier Exit (Long, 3 ATRs) 0.71
    Chandelier Exit (Short, 3 ATRs) 0.86
    Upper Bollinger Bands 0.87
    Lower Bollinger Band 0.68
    Percent B (%b) 0.0
    BandWidth 24.47
    MACD Line -0.05
    MACD Signal Line -0.04
    MACD Histogram -0.0088
    Fundamentals Value
    Market Cap 48.9 Million
    Num Shares 72 Million
    EPS -1.89
    Price-to-Earnings (P/E) Ratio -0.36
    Price-to-Sales 3.14
    Price-to-Book 0.93
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.73
    Resistance 3 (R3) 0.73 0.72 0.72
    Resistance 2 (R2) 0.72 0.71 0.72 0.72
    Resistance 1 (R1) 0.70 0.70 0.69 0.70 0.71
    Pivot Point 0.69 0.69 0.68 0.68 0.69
    Support 1 (S1) 0.67 0.67 0.66 0.66 0.64
    Support 2 (S2) 0.65 0.67 0.65 0.64
    Support 3 (S3) 0.63 0.65 0.64
    Support 4 (S4) 0.63